Search Results
Nov 18, 2025, 07:30 ET Akadeum Life Sciences Announces Drug Master File Submission to the US FDA for GMP Microbubble Cell Separation
commitment to delivering high-quality cell isolation products for cell therapy workflows, ongoing adherence to standards for Ancillary Materials in Cell and Gene Therapy, and support of customers actively pursuing clinical trials with Akadeum's microbubbles.
More news about: Akadeum Life Sciences
Nov 18, 2025, 07:00 ET Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in
More news about: Genprex, Inc.
Nov 18, 2025, 07:00 ET TITAN Containers introduces ArcticStore Horizon, believed to be the World's Most Environmentally Friendly Portable Cold Room
massive shift from traditional small-molecule drugs to complex, ultra-low temperature-sensitive large-molecule biopharmaceuticals, including cell and gene therapies. The growth of the cold storage market is tempered by several headwinds, including growing energy costs and limited
More news about: TITAN Containers
Nov 18, 2025, 05:40 ET Oncology Molecular Diagnostics Market to Reach US$ 6.46 Billion by 2033, Driven by Precision Oncology, and Accelerating Biomarker-Based Therapies - According to DataM Intelligence
laboratories for actionable biomarker detection. However, NGS is the fastest-growing technology, supported by the industry's shift toward multi-gene panels, whole-genome sequencing (WGS), and liquid biopsy-based solutions. In situ hybridization (ISH) and other platforms continue to provide value
More news about: DataM Intelligence 4 Market Research LLP
Nov 18, 2025, 04:03 ET OCHRE BIO COMPLETES HUMAN LIVER FUNCTIONAL GENOMICS AND SINGLE-CELL DATASETS IN PARTNERSHIP WITH GSK
proprietary OBELiX software further integrates these datasets with proprietary disease atlases, combining gene perturbation data with clinical phenotypes. Together, these resources enable a causal mapping of gene function to proprietary disease signatures across pathways and cell types. By
More news about: Ochre Bio
Nov 17, 2025, 13:01 ET Cincinnati Children's accelerating breakthroughs in care for cancer, blood diseases and genetic disorders with new center
pediatric cancer care, acquired and renovated a large building in Sharonville, Ohio, to expand the Applied Gene and Cell Therapy Center. It's four times bigger and has far greater capacity to manufacture gene, cell and immunotherapy therapy products than the facility in Cincinnati's Avondale neighborhood where
More news about: Cincinnati Children's Hospital Medical Center
Nov 17, 2025, 10:45 ET Pharmaceutical Quality Management Software Market worth $2.98 billion by 2030 with 13.3% CAGR | MarketsandMarkets™
insights across sites. These solutions support diverse pharmaceutical applications, including biotechnology, biopharma, medical devices, and cell and gene therapy, ensuring adherence to regulatory standards while streamlining complex workflows. The company provides pharma QMS solutions through industrial
More news about: MarketsandMarkets
Nov 17, 2025, 09:30 ET LevelField Bank Approved to Offer Business and Consumer Banking and Digital Asset Services in all U.S. States and Territories
best‑in‑class, true 24x7 bank delivering real‑time payment and banking functionality for customers, including historically underbanked businesses," said Gene A. Grant II, CEO of LevelField Financial. "Today's approval is an important milestone for LevelField. I am grateful to our investors and partners for
More news about: LevelField Financial
Nov 17, 2025, 09:12 ET Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and United States, providing support across gene therapy, APIs, and both large and small molecule manufacturing. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities
More news about: Ajinomoto Bio-Pharma Services
Nov 17, 2025, 08:59 ET Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and United States, providing support across gene therapy, APIs, and both large and small molecule manufacturing. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities
More news about: Ajinomoto Bio-Pharma Services
Nov 17, 2025, 08:15 ET Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The INN nomenclature scheme for CAR-T cell therapies follows a two-word structure describing the gene and cell component.
More news about: Anixa Biosciences, Inc.
Nov 17, 2025, 07:15 ET BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025
BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced that management will participate in the following investor conferences during November and December:
More news about: BioLife Solutions, Inc.
Nov 17, 2025, 07:00 ET Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025
address accessibility for gene therapies, such as Nanoscope's MCO-010. Following are the details for each presentation and panel discussion: Keynote Panel: "State of the Industry Address for Cell and Gene Therapies"Presenter:
More news about: Nanoscope Therapeutics
Nov 17, 2025, 06:00 ET Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
molecule. The FDA granted Breakthrough Therapy designation for zanidatamab's development in patients with previously treated HER2 gene-amplified BTC, and two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care
More news about: Jazz Pharmaceuticals plc
Nov 16, 2025, 13:05 ET Post Malone To Perform Red Kettle Kickoff Halftime Show During Dallas Cowboys Thanksgiving Day Game
father, Rich Post, took a job with the Dallas Cowboys as the assistant director of food and beverage at AT&T Stadium and remained close with the Gene and Jerry Jones family and the Cowboys organization. "I'm from Texas. I grew up a Cowboys fan and have been watching this halftime
More news about: The Salvation Army
Nov 16, 2025, 13:05 ET Post Malone actuará en el espectáculo de medio tiempo que dará inicio oficial a la campaña Red Kettle durante el partido del Día de Acción de Gracias de los Dallas Cowboys
aceptara el puesto de subdirector de alimentos y bebidas de los Dallas Cowboys en el estadio AT&T, donde mantuvo una estrecha relación con la familia Gene y Jerry Jones así como con la organización de los Cowboys. «Soy de Texas. Crecí como aficionado de los Cowboys y llevo años viendo
More news about: The Salvation Army
Nov 15, 2025, 13:38 ET Die Fondazione Telethon gibt bekannt, dass der CHMP eine positive Stellungnahme zu Waskyra™ abgegeben hat, einer Gentherapie zur Behandlung des Wiskott-Aldrich-Syndroms (WAS)
Die Therapie wurde im Rahmen jahrzehntelanger Forschung am San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Mailand entwickelt und stellt eine bedeutende wissenschaftliche und klinische Errungenschaft dar, die Patienten, die von dieser
More news about: Fondazione Telethon
Nov 15, 2025, 13:30 ET La Fondazione Telethon annonce l'avis positif du CHMP pour Waskyra™, une thérapie génique pour le traitement du syndrome de Wiskott-Aldrich (WAS)
Wiskott-Aldrich est une maladie génétique rare du sang qui provoque une immunodéficience et une faible numération plaquettaire, résultant de mutations du gène WAS. La maladie se manifeste dès la petite enfance par des infections récurrentes et persistantes, des épisodes hémorragiques, de l'eczéma et un risque
More news about: Fondazione Telethon
Nov 14, 2025, 15:57 ET Emmaus Life Sciences Reports Quarterly Financial Results
DiseaseThere are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300
More news about: Emmaus Life Sciences, Inc.
Nov 14, 2025, 10:24 ET Fondazione Telethon annuncia il parere positivo del CHMP per Waskyra™, terapia genica per il trattamento della sindrome di Wiskott-Aldrich (WAS)
sindrome di Wiskott-Aldrich è una rara malattia genetica del sangue che causa immunodeficienza e un basso numero di piastrine, dovuta a mutazioni nel gene WAS. La malattia si manifesta fin dalla prima infanzia con infezioni ricorrenti e persistenti, sanguinamenti, eczema e un aumentato rischio di sviluppare
More news about: Fondazione Telethon
Nov 14, 2025, 10:23 ET LAST CALL: Join Nobel Laureate & Global Leaders to Explore the Next Era of Cell & Gene Therapy in London
2nd panel: Gene Therapy and mRNA Therapeutics Explore how gene and mRNA therapies are translating promise into practice, tackling challenges in delivery, durability,
More news about: GenScript Biotech Corporation
Nov 14, 2025, 10:03 ET Fondazione Telethon announces CHMP positive opinion for Waskyra™, a gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS)
patients at IRCCS Ospedale San Raffaele, a recognized center of excellence in gene therapy for this and other diseases, where the clinical trial phase was conducted. The BLA for the same gene therapy for WAS remains under review by the U.S. Food and Drug Administration (FDA).
More news about: Fondazione Telethon
Nov 14, 2025, 10:01 ET Cardiovascular Biologics Market Expected to Reach USD 4.23 Billion by 2033 Amid Advances in RNA and Biologic Therapies | DataM Intelligence
This growth is driven by the increasing development of biologic and gene-based therapies targeting cardiovascular disease (CVD) pathways, including monoclonal antibodies (mAbs), siRNA-based therapeutics, recombinant proteins
More news about: DataM Intelligence 4 Market Research LLP
Nov 14, 2025, 04:17 ET uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
investors. On November 3, 2025, uniQure issued a press release concerned a pre-Biologics License Application (BLA) meeting with the FDA about AMT-130, its gene therapy for Huntington's disease (HD). According to the Company, it "believes that the FDA currently no longer agrees that data from the Phase I/II
More news about: DJS Law Group LLP
Nov 14, 2025, 03:36 ET Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
Vyepti® (eptinezumab) Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was intentionally designed for IV administration. The efficacy and safety of eptinezumab was evaluated in two Phase 3 clinical
More news about: H. Lundbeck A/S